Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Generic Name
- Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Indication
用于：1.恶性肿瘤、白血病化、放疗引起的白血病减少及其并发的感染；
2.造血干/祖细胞移植后髓系造血功能受抑及延迟植活与移植排斥；
3.与rhG-CSF等造血生长因子联合或单独应用于外周血造血干/祖细胞移植前的干/祖细胞动员；
4.再生障碍性贫血等骨髓衰竭性疾患及各种严重感染并发的中性粒细胞减少；
5.也可用于艾滋病本身、或因药物治疗所致的中性粒细胞减少。
Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 8
- Registration Number
- NCT02451488
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
- Conditions
- Advanced CancerAdvanced Malignancies
- Interventions
- Radiation: Hypofractionated radiotherapy
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 398
- Registration Number
- NCT02383212
- Locations
- 🇺🇸
Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Cancer Insight, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT02297698
- Locations
- 🇺🇸
Florida Cancer Research Institute, Plantation, Florida, United States
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Memorial Hospital of South Bend, South Bend, Indiana, United States
Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
- Conditions
- Malignant Melanoma
- Interventions
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Ultimovacs ASA
- Target Recruit Count
- 12
- Registration Number
- NCT02275416
- Locations
- 🇳🇴
Oslo University Hospital, Radiumhospitalet, Oslo, Norway
Inhalation of Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Autoimmune Pulmonary Alveolar Proteinosis (PAP)
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT02243228
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
- Conditions
- Neuroblastoma
- Interventions
- Biological: Anti-GD2 3F8 Monoclonal Antibody
- First Posted Date
- 2014-04-01
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 69
- Registration Number
- NCT02100930
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
- First Posted Date
- 2013-12-12
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- University of Louisville
- Target Recruit Count
- 27
- Registration Number
- NCT02009397
- Locations
- 🇺🇸
James Graham Brown Cancer Center, Louisville, Kentucky, United States
Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma
- First Posted Date
- 2013-09-11
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT01939730
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2013-07-26
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- UbiVac
- Target Recruit Count
- 12
- Registration Number
- NCT01909752
- Locations
- 🇺🇸
LSU Stanley S. Scott Cancer Center, New Orleans, Louisiana, United States
🇺🇸Providence Cancer Center, Portland, Oregon, United States
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
- Conditions
- GlioblastomaGliosarcoma
- Interventions
- Drug: Oral Control (Sucrose pill)Drug: Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))Drug: Bevacizumab/Bevacizumab Biosimilar
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Epitopoietic Research Corporation
- Target Recruit Count
- 84
- Registration Number
- NCT01903330
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸University of California, Irvine, Orange, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.